Tedatioxetine
Tedatioxetine is in phase I clinical trials for the treatment of major depression, generalized anxiety disorder.
Tedatioxetine had been in phase II clinical trials for the treatment of major depression. However, Lundbeck decided to discontinue this indication for strategic reasons in 2014
The compound was originally developed by Lundbeck. Then it was co-developed by Lundbeck and Takeda in the U.S. and Japan.
General Information
Update Date：2016-04-11
- Drug Name：
- Tedatioxetine
- Research Code：
- Lu-AA-24530
- Trade Name：
- MOA：
- Multimodal anti-depressant
- Indication：
- Major depressive disorder (MDD); Generalised anxiety disorder (GAD)
- Status：
- Phase Ⅱ (Discontinued)
- Company：
- Takeda (Originator) , Lundbeck
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-08-24
|
Molecular Weight | 364.34 | ||||||||||||
| Formula | C18H21NS●BrH | |||||||||||||
| CAS No. |
960151-65-9 (Tedatioxetine hydrobromide); 508233-95-2 (Tedatioxetine); |
|||||||||||||
| Chemical Name | Piperidine, 4-[2-[(4-methylphenyl)thio]phenyl]-, hydrobromide (1:1) | |||||||||||||
| Tedatioxetine hydrobromide （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||